Recommended Pages at us.gsk.com
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
us.gsk.com — “GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines” View full resource at us.gsk.com
Most Recently Shared on May 1, 2012 at 1:14 pm By:
eyeonfda Pharma and Health Lawyer
GSK and Yale University establish drug discovery collaboration to design potential new class of medicines http://t.co/J4nHClFb
Awards - Health programs - Communities - GlaxoSmithKline
us.gsk.com — “Health programs provides an overview of the many GSK corporate-based programs that support health-related initiatives” View full resource at us.gsk.com
Most Recently Shared on March 6, 2012 at 7:11 pm By:
Philly area or City of Camden nonprofits offering healthcare services could win $40K. http://t.co/iXujl0vC
GlaxoSmithKline Invites Philadelphia Area and City of Camden Healthcare Nonprofits to Apply for $40,000 IMPACT Awards
us.gsk.com — “GlaxoSmithKline Invites Philadelphia Area and City of Camden Healthcare Nonprofits to Apply for $40,000 IMPACT Awards” View full resource at us.gsk.com
Most Recently Shared on March 6, 2012 at 6:59 pm By:
GSK invites Philly Area & City of Camden healthcare nonprofits to apply for $40K IMPACT awards http://t.co/RvQB656I
Contact us - GlaxoSmithKline
us.gsk.com — “Basic contact information for consumers and professionals” View full resource at us.gsk.com
Most Recently Shared on December 9, 2011 at 3:28 pm By:
@pharmacyfriend to report adverse events with our products please contact GSK Response Center at http://t.co/WblpjyGl or 888-825-5249
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
us.gsk.com — “Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine” View full resource at us.gsk.com
Most Recently Shared on December 1, 2011 at 3:46 pm By:
eyeonfda Pharma and Health Lawyer
GSK submits additional info to FDA for candidate meningococcal and Hib combination vaccine http://t.co/7O2I9g7m
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
us.gsk.com — “GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease” View full resource at us.gsk.com
Most Recently Shared on September 12, 2011 at 1:09 pm By:
eyeonfda Pharma and Health Lawyer
GSK and Amicus Therapeutics commence second phase III study of Amigal™ for #Fabry disease http://ow.ly/6rLPj
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
us.gsk.com — “Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia” View full resource at us.gsk.com
Most Recently Shared on August 10, 2011 at 1:10 pm By:
eyeonfda Pharma and Health Lawyer
GSK and XenoPort submit supplemental NDA to #FDA for Horizant™ in postherpetic #neuralgia http://ow.ly/5ZEGt
GlaxoSmithKline pledges $10 million at White House meeting on US education reform
us.gsk.com — “GlaxoSmithKline pledges $10 million at White House meeting on US education reform” View full resource at us.gsk.com
Most Recently Shared on July 18, 2011 at 5:06 pm By:
GSK pledges $10 million at White House meeting on US education reform http://t.co/HVj8UXN
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
us.gsk.com — “GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)” View full resource at us.gsk.com
Most Recently Shared on July 14, 2011 at 1:51 pm By:
eyeonfda Pharma and Health Lawyer
GSK and HGS get EU authorization for Benlysta® (belimumab) http://ow.ly/5Eq5m #lupus
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
us.gsk.com — “GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan” View full resource at us.gsk.com
Most Recently Shared on July 1, 2011 at 1:36 pm By:
eyeonfda Pharma and Health Lawyer
GSK announces new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan http://ow.ly/5uKdj
Regulatory update -- GSK and Valeant respond to FDA on ezogabine
us.gsk.com — “Regulatory update -- GSK and Valeant respond to FDA on ezogabine” View full resource at us.gsk.com
Most Recently Shared on April 18, 2011 at 1:16 pm By:
eyeonfda Pharma and Health Lawyer
GSK and Valeant Pharmaceuticals submit response to FDA CRL for ezogabine NDA http://ow.ly/4CraX
GSK publishes payments for research, consulting and advising by US healthcare professionals
us.gsk.com — “GSK publishes payments for research, consulting and advising by US healthcare professionals” View full resource at us.gsk.com
Most Recently Shared on March 31, 2011 at 2:42 pm By:
eyeonfda Pharma and Health Lawyer
GSK publishes payments for research, consulting and advising by US healthcare professionals http://ow.ly/4qn51
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease
us.gsk.com — “GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease” View full resource at us.gsk.com
Most Recently Shared on March 15, 2011 at 1:32 pm By:
eyeonfda Pharma and Health Lawyer
GSK announces positive topline results of Phase lll study of IPX066 in advanced #Parkinson’s disease - http://ow.ly/4eOQj
David Redfern appointed as new Chairman of ViiV Healthcare
us.gsk.com — “GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer today announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st April 2011, following the retirement of Julian Heslop.” View full resource at us.gsk.com
Most Recently Shared on February 25, 2011 at 2:03 pm By:
eyeonfda Pharma and Health Lawyer
New Chairman appointed for ViiV Healthcare http://ow.ly/43jzm #HIV
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza
us.gsk.com — “GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza” View full resource at us.gsk.com
Most Recently Shared on January 19, 2011 at 2:42 pm By:
eyeonfda Pharma and Health Lawyer
GSK commences Phase III study of intravenous zanamivir for hospitalized patients with influenza http://ow.ly/3Gsjp
